{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:52:46Z","timestamp":1794264766518,"version":"4.9.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T00:00:00Z","timestamp":1717891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022963","name":"Key R&D Plan in Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013145","name":"Primary Research and Development Plan of Zhejiang Province","doi-asserted-by":"publisher","award":["2020C03034"],"award-info":[{"award-number":["2020C03034"]}],"id":[{"id":"10.13039\/501100013145","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.xkme.2024.100853","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T19:32:12Z","timestamp":1718739132000},"page":"100853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Obinutuzumab in Refractory Membranous Nephropathy: A Case Series"],"prefix":"10.1016","volume":"6","author":[{"given":"Yuxin","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaomin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-7556","authenticated-orcid":false,"given":"Fei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xkme.2024.100853_bib1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1681\/ASN.2020071082","article-title":"New \u201dantigens\u201d in membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2024.100853_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.xkme.2024.100853_bib3","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ekir.2020.12.035","article-title":"Rituximab in membranous nephropathy","volume":"6","author":"Gauckler","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1016\/j.xkme.2024.100853_bib4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ctrv.2015.07.003","article-title":"Obinutuzumab in hematologic malignancies: lessons learned to date","volume":"41","author":"Illidge","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.xkme.2024.100853_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2017-03-771832","article-title":"Obinutuzumab: what is there to learn from clinical trials?","volume":"130","author":"Cartron","year":"2017","journal-title":"Blood"},{"issue":"4s","key":"10.1016\/j.xkme.2024.100853_bib6","first-page":"S1","article-title":"KDIGO 2021 Clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.xkme.2024.100853_bib7","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1016\/j.xkme.2024.100853_bib8","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2024.100853_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: a report of 3 cases","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.xkme.2024.100853_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-022-02761-3","article-title":"Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases","volume":"23","author":"Hudson","year":"2022","journal-title":"BMC Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2024.100853_bib11","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ckj\/sfab250","article-title":"Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab","volume":"15","author":"Ginth\u00f6r","year":"2022","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.xkme.2024.100853_bib12","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ekir.2023.01.035","article-title":"Obinutuzumab in refractory phospholipase A2 receptor-associated membranous nephropathy with severe CKD","volume":"8","author":"Naik","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.xkme.2024.100853_bib13","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ekir.2021.01.022","article-title":"Analysis and management of rituximab resistance in PLA2R1-associated membranous nephropathy","volume":"6","author":"Teisseyre","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1016\/j.xkme.2024.100853_bib14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40265-023-01855-y","article-title":"Update on the application of monoclonal antibody therapy in primary membranous nephropathy","volume":"83","author":"Deng","year":"2023","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.xkme.2024.100853_bib21","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.ekir.2022.08.006","article-title":"Circulating anti-rituximab antibodies do not affect response to rituximab in steroid-dependent nephrotic syndrome","volume":"7","author":"Angeletti","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"5 Pt 1","key":"10.1016\/j.xkme.2024.100853_bib15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.xkme.2024.100853_bib16","first-page":"1463","article-title":"Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders","volume":"17","author":"Said","year":"2017","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.xkme.2024.100853_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A\u00a0tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.xkme.2024.100853_bib18","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.xkme.2024.100853_bib19","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.xkme.2024.100853_bib20","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059524000645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059524000645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T18:17:00Z","timestamp":1723054620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059524000645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2590059524000645"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2024.100853","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obinutuzumab in Refractory Membranous Nephropathy: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2024.100853","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100853"}}